✦ LIBER ✦

Neoadjuvant trastuzumab + FEC for HER2-positive breast cancer

Book ID: 120855081
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2005
Weight: 138 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200514850-00025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fluorouracil, epirubicin, and cyclophosp

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

✍ Buzdar, Aman U; Suman, Vera J; Meric-Bernstam, Funda; Leitch, A Marilyn; Ellis, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 178 KB

Adjuvant trastuzumab for HER2-positive b

Adjuvant trastuzumab for HER2-positive breast cancer

✍ James Spicer; Mark Harries; Paul Ellis 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 47 KB

Trastuzumab-based neoadjuvant therapy in

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

✍ Helena R. Chang 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB 👁 2 views

Adjuvant Trastuzumab Therapy for HER2-Po

Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer

✍ Mohammad Jahanzeb 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 148 KB

Trastuzumab Emtansine for HER2-Positive

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

✍ Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselg 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 365 KB

Duration of trastuzumab for HER2-positiv

Duration of trastuzumab for HER2-positive breast cancer

✍ Montemurro, Filippo; Aglietta, Massimo 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 203 KB